missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SIGLEC15 Biosimilar Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
477.00€ - 1204.00€
Spécification
| Antigène | SIGLEC15 Biosimilar |
|---|---|
| Concentration | 1 mg/mL |
| Contenu et stockage | -20°C, Avoid Freeze/Thaw Cycles |
| Applications | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Classification | Recombinant Monoclonal |
| Code produit | Marque | Quantité | Prix | Quantité et disponibilité | |||||
|---|---|---|---|---|---|---|---|---|---|
| Code produit | Marque | Quantité | Prix | Quantité et disponibilité | |||||
30283072
![]() |
Invitrogen™
MA558397 |
100 μg |
477.00€
100µg |
Veuillez vous connecter pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant! | |||||
|
30282463
|
Invitrogen™
MA558398 |
1 mg |
1204.00€
1mg |
Veuillez vous connecter pour pouvoir commander cet article. Besoin d'un compte web? Créer le vôtre dès maintenant! | |||||
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term NC318.
SIGLEC15 (Sialic acid-binding immunoglobulin-like lectin 15) is a member of the Siglec family, which is primarily involved in immune cell signaling and modulation. It is located on chromosome 18q12.2 and is highly expressed in myeloid cells, including macrophages and dendritic cells. Structurally, Siglec-15 contains a V-set and a C2-set immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic domain containing immunoreceptor tyrosine-based inhibition motifs (ITIMs). Functionally, Siglec-15 plays a crucial role in osteoclast differentiation and bone resorption, as well as in modulating immune responses. It enhances tumor immune escape by suppressing T cell activation and has been identified as a potential target for cancer immunotherapy. Overexpression of Siglec-15 is associated with various cancers, infectious diseases, and bone metabolic disorders.Spécification
| SIGLEC15 Biosimilar | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| IgG1 | |
| Human | |
| Primary | |
| Protein A |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Antibody |
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit